Genomewide screens in ankylosing spondylitis

Advances in Experimental Medicine and Biology

Volumn 649, Issue , 2009, Pages 148-158

  Brown, Matthew A ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOCHROME P450 2D6; HLA ANTIGEN; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA B60 ANTIGEN; HLA CW6 ANTIGEN; HLA DR ANTIGEN; HLA E ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 23 RECEPTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN ARTS1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REGULATOR PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; ARTS1 GENE; CASPASE RECRUITMENT DOMAIN PROTEIN 15 GENE; CYTOCHROME P450 2D6 GENE; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE SEGREGATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTERLEUKIN 1 GENE; INTERLEUKIN 23 RECEPTOR GENE; MAJOR HISTOCOMPATIBILITY COMPLEX; MARKER GENE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEGREGATION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TOLL LIKE RECEPTOR 4 GENE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HLA-B27 ANTIGEN; LINKAGE (GENETICS); MAJOR HISTOCOMPATIBILITY COMPLEX; SPONDYLITIS, ANKYLOSING;

EID: 70349576354     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0298-6_11     Document Type: Article

References (76)

1. Taurog JD, Richardson JA, Crofi JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180(6):2359-64. (Pubitemid 24351619)
2. Brown MA, Kennedy LG, MacGregor AJ et al. Susceptibility to ankylosing spondylit is in twins: the role of genes, HLA and the environment. Arthritis Rheum 1997; 40(10):1823-8. (Pubitemid 27452533)
3. Pedersen O, Svendsen A, Ejstrup L et al. Heritabilit y estimates on ankylosing spondylitis. Clin Exp Rheumarol 2006; 24(4):463.
4. Brown MA, Brophy S, Bradbury L et al. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum 2003; 48(8):2234-9. (Pubitemid 36959204)
5. Hamersma J, Cardon LR, Bradbury L et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001; 44(6):1396-400. (Pubitemid 32537539)
6. Brophy S, Hickey S, Menon A et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheurnatol 2004; 31(9):1775-8. (Pubitemid 39202520)
7. *2705. AIDS 1998; 12(11):1391-3. (Pubitemid 28330734)
8. Risch N. Linkage strategies for genetically complex traits I. Multilocus models. Am J Hum Genet 1990; 46(2):222-8.
9. Brown MA, Laval SH, Brophy S et al. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000; 59( 11):883-6.
10. Lander ES, Botstein D. Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms. Proc Natl Acad Sci USA 1986; 83(19):7353-7. (Pubitemid 16000520)
11. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411(6837):599-603. (Pubitemid 32531408)
12. Laurin N, Brown JP, Morissette J et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70(6):1582-8. (Pubitemid 34533906)
13. Ferrari SL, Deutsch S, Choudhury U et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size and stature in whites. Am J Hum Genet 2004; 74(5):866-75. (Pubitemid 38568961)
14. Koay M, Woon P-Y, Zhang Y et al. Influence of LRP5 polymorphisms on normal variation in BMD. Journal of Bone and Mineral Research 2004; 19(10):1619-1627. (Pubitemid 41094324)
15. Little R, Carulli J, Del Mastro R et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11-19. (Pubitemid 34031693)
16. Consortium WTCC. Genomewide association study of 14, 000 cases of seven common diseases and 3000 controls. Nature 2007; 447:661-83.
17. Zhang G, Luo J, Bruckd J et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum 2004; 50(7):2246-54. (Pubitemid 38924403)
18. Miceli-Richard C, Zouali H, Said-Nahal R et al. Significant linkage to spondyloarthropathy on 9q31-34. Hum Mol Genet 2004; 13(15):1641-8. (Pubitemid 39136720)
19. Laval SH, Timms A, Edwards S et al. Whole-genome screening in ankylosing spondylitis: evidence of nonMHC genetic-susceptibility loci. Am J Hum Genet 2001; 68(4):918-26. (Pubitemid 32289738)
20. Brown MA, Pile KD, Kennedy LG et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998; 41(4):588-95. (Pubitemid 28214976)
21. Carter KW, Pluzhnikov A, Timms AE et al. Combined analysis of three whole genome linkage scans for Ankylosing Spondylitis. Rheumatology (Oxford) 2007; 46(5):763-71. (Pubitemid 47061705)
22. Timms AE, Crane AM, Sims AM et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75(4):587-95. (Pubitemid 39244773)
23. van der Paardt M, Crusius JB, Garcia-Gonzalez MA et al. Inrerleukin-1beta and ineerleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2002; 41(12):1419-23. (Pubitemid 36004320)
24. McGarry F, Neilly J, Anderson N et al. A polymorphism within the interleukin 1 receptor antagonist (IL-IRa) gene is associared with ankylosing spondylitis. Rheumatology (Oxford) 2001; 40(12):1359-64.
25. Chou CT, Timms AE, Wei JC et al. Replication of association of IL1 gene complex members with ankylosing spondylitis in taiwanese chinese. Ann Rheum Dis 2006; 65(8):1106-9. (Pubitemid 44133277)
26. Brown MA, Edwards S, Hoyle E et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000; 9(11):1563-6. (Pubitemid 30426992)
27. Beyeler C, Armstrong M, Bird HA et al. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996; 55(1):66-8.
28. WTCCC, TASC. A genome-wide scan of 14, 000 nonsynonymous coding SNPs in 5, 500 individuals: The Wellcome Trust Case Control Consortium. Nat Genet 2007; 39(11):1329-37.
29. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T-cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6(11):1133-41. (Pubitemid 41541791)
30. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924):744-8. (Pubitemid 36227625)
31. Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198(12):1951-7. (Pubitemid 38032126)
32. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314(5804):1461-3. (Pubitemid 44871953)
33. Tremelling M, Cummings F, Fisher SA et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007; 132(5):1657-1664. (Pubitemid 46695721)
34. Cargill M, Schrodi S, Chang M et al. A large-scale genetic association study confirms ILl2B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80(2):273-290. (Pubitemid 46175676)
35. Reveille JD, Zhou X. McGinnis R et al. Interleukin-23 receptor polymorphisms are a major determinant of susceptibility to ankylosing spondylitis. Nat Genet 2007; Submitted.
36. de Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27(12):2860-5.
37. Palm O, Mourn B, Ongre A et al. Prevalence of ankylosing spondylitis and other spondyloarthroparhies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29(3):511-5. (Pubitemid 34202820)
38. Salvarani C, Vlachonikolis IG, van der Heijde DM et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001; 36(12):1307-13. (Pubitemid 33027811)
39. Scarpa R, del Puente A, D'Arienzo A et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992; 19(3):373-7.
40. Steer S, Jones H, Hibbert J et al. Low back pain, sacroiliitis and the relationship with HLA-B27 in Crohn's disease. J Rheurnatol 2003; 30(3):518-22. (Pubitemid 36301944)
41. Thjodleifsson B, Geirsson AJ, Bjornsson S et al. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007; 56(8):2633-9. (Pubitemid 47237281)
42. Hammer GE, Gonzalez F, Champsaur M et al. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 2006; 7(1):103-12. (Pubitemid 41823874)
43. Kanaseki T, Blanchard N, Hammer GE er al. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006; 25(5):795-806. (Pubitemid 46107289)
44. Cui X, Rouhani FN, Hawari F et al. Shedding of the type II IL-l decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003; 171(12):6814-9. (Pubitemid 37532116)
45. Cui X, Rouhani FN, Hawari F et al. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Bioi Chem 2003; 278(31):28677-85. (Pubitemid 36935774)
46. Cui X, Hawari F, Alsaary S et al. Identification of ARTS-l as a novel TNFRl-binding protein that promotes TNFRI ecrodomain shedding. J Clin Invest 2002 ; 110(4):515-26. (Pubitemid 34919706)
47. Vazquez-Dei MM, Garcia-Gonzalez A, Munoz-Valle JF et al. Inrerleukin Ibeta (IL-lbeta), IL-10, rumor necrosis factor-alpha and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 2002; 29(3):522-6. (Pubitemid 34207681)
48. Maksymowych WP, Rahman P, Reeve JP et al. Association of the ILl gene cluster with susceptibility to ankylosing spondylitis: an analysis of three canadian populations. Arthritis Rheum 2006; 54(3):974-85.
49. Rahman P, Sun S, Peddle L et al. Association between the inrerleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006; 54(7):2321-5. (Pubitemid 44051093)
50. Sims A-M, Timms A, Bruges Armas J et al. Prospective meta-analysis of IL-l gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 2007; Submitted.
51. Timms AE, Zhang Y, Bradbury L et al. Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 2003; 48(10):2898-902. (Pubitemid 37280619)
52. Tsui FW, Tsui HW, Cheng EY et al. Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003; 48(3):791-7. (Pubitemid 36302017)
53. Adam R, Sturrock RD, Gracie JA. TLR4 mutations (Asp299Gly and Thr399Ile) are not associated with ankylosing spondylitis. Ann Rheum Dis 2006; 65(8):1099-101. (Pubitemid 44133275)
54. Gergely P Jr, Blazsek A, Weiszhar Z et al. Lack of genetic association of the Toll-like receptor 4 (TLR4) Asp299Gly and Thr399lle polymorphisms with spondylarthropathies in a Hungarian population. Rheumatology (Oxford) 2006; 45(10):1194-6. (Pubitemid 44542058)
55. Snelgrove T, Lim S, Greenwood C et al. Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study. J Rheurnarol 2007; 34(2):368-70.
56. van der Paardt M, Crusius JB, de Koning MH et al. No evidence for involvement of the Toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Ann Rheum Dis 2005; 64(2):235-8. (Pubitemid 40193619)
57. Crane AM, Bradbury L, van Heel DA et al. Role ofNOD2 variants in spondylarthritis. Arthritis Rheum 2002; 46(6):1629-33.
58. Miceli-Richard C, Zouali H, Lesage S et al. CARDI5/NOD2 analyses in spondylarchroparhy, Arthritis Rheum 2002; 46(5):1405-6.
59. van der Paardt M, Crusius JB, de Koning MH et al. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 2003; 4(1):77-8. (Pubitemid 38967578)
60. van Heel DA, McGovern DP, Cardon LR et al. Fine mapping of the IBD 1 locus did not identify Crohn disease-associated NOD2 variants: implications for complex disease genetics. Am J Med Genet 2002; 111(3):253-9. (Pubitemid 34815448)
61. van Heel DA, Dechairo BM, Dawson G et al. The IBD6 Crohn's disease locus demonstrates complex interactions with CARD15 and IBD5 disease-associated variants. Hum Mol Genet 2003; 12(20):2569-75. (Pubitemid 37304680)
62. D'Amato M. The Crohn's associated NOD2 3020InsC frameshifi mutation does not confer susceptibility to ankylosing spondylitis. J Rheumatol 2002; 29(11):2470-1. (Pubitemid 35266049)
63. Ferreiros-Vidal I, Amarelo J. Barros F et al. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J Rheumatol 2003; 30(1):102-4. (Pubitemid 36077779)
64. Peeters H, Vander Cruyssen B, Laukens D et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004; 63(9):1131-4. (Pubitemid 39120367)
65. Kim TH, Rahman P, Jun JB et al. Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in western populations. J Rheumarol 2004; 31(10):1959-61. (Pubitemid 39336720)
66. Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC et al. Contribution ofKIR3DU/3DSI to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther 2006; 8(4):R101.
67. Brown MA, Pile KD, Kennedy LG et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55(4):268-70. (Pubitemid 26120706)
68. Robinson WP, van der Linden SM, Khan MA et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989; 32(9):1135-41. (Pubitemid 19237868)
69. Wei JC, Tsai WC, Lin HS et al. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheumatology (Oxford) 2004; 43(7):839-42. (Pubitemid 38996956)
70. Brown MA, Kennedy LG, Darke C et al. The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis Rheum 1998; 41(3):460-5. (Pubitemid 28128771)
71. Ploski R, Maksymowych W, Forre O. HLA-DR8 and susceptibility to acute anter ior uveitis in ankylosing spondylitis: comment on the article by Monowacul Islam et al. Arthritis Rheum 1996; 39(2):351-2.
72. Monowacul Islam SM, Numaga J, Fujino Y et al. HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. Arthritis Rheum 1995; 38(4):547-50.
73. Sims AM, Wordsworth BP, Brown MA. Genetic susceptibility to ankylosing spondylitis. Curr Mol Med 2004; 4(1):13-20. (Pubitemid 38279427)
74. D'Arnaro M, Fiorillo MT, Carcassi C et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25(11):3199-201.
75. Sims AM, Barnardo M, Herzberg I et al. Non B27 MHC associations of ankylosing spondylitis. Genes Immun 2007; 8(2):115-23. (Pubitemid 46390909)
76. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974; 99(5):325-32.